SecBot SecBot
PRESS-RELEASE ·Filed Nov 16, 2026

ALXO

ALX Oncology
BEARISH
Impact 5/10
Horizonweeks Processed5d 23h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

Watch for ALX2004 Phase 1 data release in December 2026 and the KOL webinar; positive safety/efficacy could be a catalyst. Also monitor ASPEN-09-Breast enrollment updates and any changes to cash runway guidance.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

ALXO drug pipeline →

ALX2004

● Neutral Named in this press release
Impact
Phase
Phase 1
Time to market
At least 5-7 years if successful (currently in Phase 1 dose-escalation; typical ADC development timelines from Phase 1 to approval span 5-8 years)
Next catalyst
None dated

What to watchInvestors should watch for the Phase 1 safety data readout in 2H 2026, which will be the first clinical data for this program. Positive results could unlock a $10M contingent tranche from HSVC's $50M credit facility. The data will also validate ALXO's internal ADC platform and inform whether the drug can differentiate in a competitive EGFR-targeted ADC landscape where MRG003 (becotatug vedotin) was already approved in China in November 2025.

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$1.00
T+0 close · Nov 16, 2026 · via day close
Latest settled
+0.50%
T+1 · $1.01
Vs SPY
+1.51%
α at T+1
Next horizon
T+5
in 24h
  1. T+0 · Nov 16 $1.00entry
  2. T+1 · 5d ago +0.50%α +1.51% · $1.01
  3. T+4 · todayOpen
  4. T+5 · in 24h Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ALX Oncology reported Q3 2026 GAAP net loss of $21.8M ($0.15 per share) vs consensus EPS of -$0.13, a miss. Cash runway extended to first half 2028. Key catalysts: ALX2004 Phase 1 safety/efficacy data expected December 2026, and ASPEN-09-Breast topline data from 120 patients expected in 2H 2027.

Key Financial Metrics

EPS
−$0.15
est −$0.13 · -15.4%
Revenue
$0.00
est $0.00
Rating
miss

Key Facts

  • Q3 2026 GAAP net loss of $21.8M ($0.15 per share) vs consensus EPS of -$0.13 (miss).
  • Cash, cash equivalents and investments of $147.2M, sufficient to fund operations through first half of 2028.
  • R&D expenses of $17.5M, essentially flat YoY.
  • ALX2004 Phase 1 dose-escalation safety and early efficacy data expected December 2026.
  • ASPEN-09-Breast topline data from 120 patients expected in second half of 2027.
  • Non-GAAP net loss of $18.9M for Q3 2026 vs $19.6M in Q3 2025.

Financial Impact

Q3 2026 GAAP net loss of $21.8M ($0.15 per share) vs consensus EPS of -$0.13; cash burn rate of ~$7.6M per month.

net losscash runwayR&D expenses

Risk Factors

  • EPS miss vs consensus indicates higher-than-expected operating losses.
  • Clinical-stage biotech with no approved products; pipeline risk for both evorpacept and ALX2004.
  • Cash runway only through first half of 2028; potential need for future capital raises.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3403470

Track record

17 reports on ALXO

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +25.96% at T+20 after the May 8, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 19, 20262d ago SC 13G Neutral 4/10 Entry $0.9714 Now $1.06 +9.12% settles Nov 30
  2. Nov 16, 20265d ago Press Release Bearish 5/10 Viewing Entry $1.00 Now $1.06 −6.00% settles Nov 23
  3. Oct 16, 20265w ago SC 13D/A Neutral 4/10 Entry $1.14 to $1.13 Now $1.06 −7.02% ▼ −0.88% −0.73% vs SPY
  4. Oct 15, 20265w ago 8-K Mixed 6/10 Entry $1.06 to $1.17 Now $1.06 −0.00% ▲ +10.38% +10.81% vs SPY
  5. Sep 28, 20267w ago Press Release Mixed 5/10 Entry $1.39 to $1.21 Now $1.06 −23.74% ▼ −12.95% −14.15% vs SPY
  6. Aug 15, 202614w ago Institutional Cluster Neutral 4/10 Entry $1.97 to $1.99 Now $1.06 −46.19% ▲ +1.02% +2.21% vs SPY
  7. Aug 6, 202615w ago 8-K Neutral 4/10 Entry $2.11 to $1.94 Now $1.06 −49.76% ▼ −8.06% −9.27% vs SPY
  8. Jun 30, 202620w ago 8-K Neutral 3/10 Entry $2.06 to $2.36 Now $1.06 −48.54% ▲ +14.56% +14.30% vs SPY
  9. Jun 26, 202621w ago 8-K Neutral 5/10 Entry $2.20 to $2.19 Now $1.06 −51.82% ▼ −0.45% −1.84% vs SPY
  10. Jun 12, 202623w ago Institutional Cluster Bearish 5/10 Entry $1.58 to $1.53 Now $1.06 +32.91% ▲ +3.16% +3.84% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Mon (26h 20m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 16, 2026